TABLE 3.

Risk of neuropsychiatric events in relation to leukotriene receptor antagonist (LTRA) use in patients with asthma or allergic rhinitis according to age group

	Children (3–11 years)				Adolescents (12–18 years)				Young adults (19–30 years)
	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value	Events (n)	Person-years	IRR (95% CI)	p-value
Unexposed	2467	6393.79	1		3345	8101.2	1		15 216	35 051.9	1
Exposed	105	378.82	0.66 (0.53–0.80)	<0.001	118	251.11	1.28 (1.05–1.55)	0.014	348	826.05	1.14 (1.02–1.28)	0.019
Time since initiation of LTRA (days)
1–3	15	107.73	0.34 (0.20–0.55)	<0.0001	23	71.96	0.84 (0.54–1.23)	0.399	77	265.02	0.78 (0.62–0.97)	0.029
4–7	24	58.84	0.99 (0.64–1.45)	0.970	32	37.69	2.27 (1.56–3.17)	<0.001	124	131.86	2.52 (2.10–3.00)	<0.001
8–14	23	62.37	0.89 (0.57–1.31)	0.570	29	36.83	2.13 (1.43–3.03)	<0.001	81	122.80	1.76 (1.40–2.19)	<0.001
15–30	19	68.37	0.65 (0.40–0.99)	0.064	15	41.68	0.97 (0.55–1.57)	0.912	32	134.72	0.63 (0.44–0.88)	0.010
31–90	16	60.57	0.61 (0.35–0.97)	0.054	14	40.94	0.94 (0.52–1.55)	0.823	21	117.63	0.47 (0.29–0.71)	<0.001
>90	8	20.94	0.90 (0.40–1.78)	0.784	5	22.01	0.62 (0.21–1.43)	0.315	13	54.03	0.66 (0.35–1.13)	0.158

IRR: incidence rate ratio.